07 28 21 -- No CMOs Or CROs: A Unique Approach To Cell Therapy Development clinicalleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicalleader.com Daily Mail and Mail on Sunday newspapers.
05.26.21 How Takeda Is Expanding Its Real-World Data Through A Global Myeloma Trial
Combining drugs that may have been shelved with established, safe, and approved drugs has the potential to bring safer, effective therapies to patients. Attend this webinar to learn more about key trends, understanding technical challenges, and shortening timelines by smart working in parallel for scale-up and late-phase development. Click here to register.
Featured Editorial
By Dawn Marie Stull, Takeda Oncology
There is more focus than ever before on tailoring treatment plans to the unique needs of patients. One way to ensure that we as an industry are delivering the most value is by examining real-world data (RWD) throughout the drug development process.
03.08.21 Appili s CRO Selection Reflects Realities Of Clinical Studies In A Pandemic
Orphan drugs are notorious for their high costs and risk factors, which are attributed to smaller patient pools and higher development and launch costs.
Attend this webinar to learn more about key trends that are causing the rise of orphan drug indications, fast-tracking early development phases that will lead to commercial success, and more!
By Ed Miseta, chief editor, Clinical Leader
When Appili Therapeutics was ready to enter a Phase 3 trial for a COVID-19 treatment, the CRO selection process was tightly linked to the fact that the company would be conducting the study on infected patients during a global pandemic.
02.03.21 Pharma s Investment In RWE Is Beginning To Pay Off
With the spread of SARS-CoV-2 (COVID-19) intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring life-saving drugs to market. Attend this webinar to learn more about bringing life-saving drugs to market faster without impacting product quality, safety, or efficacy and the impacts and comparisons of classic platforms vs. new-generation platforms. And more!
By Ed Miseta, chief editor, Clinical Leader
For years, the life sciences industry has heard about the benefits of investing in real-world evidence (RWE) and real-world data (RWD). According to a recent report from Deloitte, that investment may finally be paying off for companies that climbed on board and have been building those capabilities.